Sterile Injectables Market

Posted by ahila on May 1st, 2018


Global Sterile Injectables Market: By Molecule Type (Large Molecules, Small Molecules), Drug Type (Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Blood Factors, Vaccines, Immunoglobulins, Peptide Antibiotics, and Others), Disease Indication (Cancer, Diabetes, Cardiovascular Diseases, Musculoskeletal, CNS, Infections, and Others), Route of Administration (Intravenous (IV), Intramuscular (IM), Subcutaneous (SC), and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Geography – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

 Sterile Injectables Market Report Description:

 Sterile Injectables market report gives a comprehensive outlook on sterile injectable across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). This report on the sterile injectable market gives historical, current, and future market sizes (US$ Mn) of drug molecules, drug types, disease application, route of administration, end users, and geographic regions. This report studies sterile injectable market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the sterile injectable market report includes drug pipeline analysis, regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analysed sterile injectable market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the sterile injectable market report include suppliers, manufacturers, marketers, policymakers engaged in manufacturing and supply of sterile injectables.

A sample of this report is available upon request @

Sterile Injectables Market:

The sterile injectable market estimated to be valued US$ 361 Bn in 2016 and poised to grow at CAGR 7.3%. The market for sterile injectable projected to reach US$ 552 Bn by 2023.

Do the burgeoning product pipelines and drug patent expiries have a positive impact on the market?

The rising shift of pharmaceutical and biotechnology firms towards the development of medications for chronic diseases such as cancer, diabetes, and cardiovascular and among others have created ample growth opportunities for players in the market. Moreover, biologic have become a larger part of product pipelines of several drug developers, which could affect market growth positively over the forecast period. For instance, there are around 2,500 injectable products are in the developmental stage. Moreover, rising product patent expiries of several blockbusters in recent times expected to propel market growth over the forecast period. For instance, in 2015, Teva Pharmaceutical Industries Ltd. lost the patent for its top-selling multiple sclerosis drug Copaxone.

How operational and installation cost effects the sterile injectable market?

Several industry experts noted that the cost of establishing sterile injectable plants is significantly higher viz-a-viz non-sterile manufacturing plants owing to stringent aseptic requirements and complex manufacturing process; this has led to the consolidation of the industry by backward and forward integration. Moreover, competition from low-cost manufacturers, value chain integration coupled with high entry barrier for new players in the sterile injectable market expect impact market growth negatively over the forecast period.

North America accounts for larger market revenue share in global sterile injectable market

North America leads the global sterile injectable market in terms of revenue in 2016. Regions such as Asia Pacific and Europe presented better growth opportunities for the market players owing to conducive business policies and increased local production generic injectable. For instance, in 2013, Mylan Inc. completed the acquisition of the Agila injectables businesses from Strides Arcolab Limited.

To view TOC of this report is available upon request @

Like it? Share it!


About the Author

Joined: March 20th, 2018
Articles Posted: 168

More by this author